سعر الفابرنزيما 1%/0.2% نقط للعين 5 مل 2025

Fixed-combination eye drops (ophthalmic suspension) of brinzolamide 1% and brimonidine tartrate 0.2% in a 5 ml bottle, marketed in Egypt by Orchidia for lowering intraocular pressure.

• Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertensionPopulation: Adults and children 2 years and older (US label)DailyMed (U.S. National Library of Medicine)

• Most common (about 3-5%): blurred vision, eye irritation, dysgeusia (bad taste), dry mouth and eye allergy; about 11% of patients discontinued because of adverse reactions in clinical trials.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Neonates and infants under 2 years of age.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Sulfonamide hypersensitivity: brinzolamide is a sulfonamide and is absorbed systemically; serious sulfonamide reactions may occur; discontinue if signs of serious reactions or hypersensitivity occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Corneal endothelium: carbonic anhydrase inhibitors may affect corneal hydration; use with caution in patients with low endothelial cell counts (risk of corneal edema).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute angle-closure glaucoma has not been studied with this product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Oral carbonic anhydrase inhibitorsPotential additive systemic effects of carbonic anhydrase inhibition; concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)
• High-dose salicylatesAcid-base and electrolyte disturbances have been reported with oral carbonic anhydrase inhibitors and high-dose salicylates.DailyMed (U.S. National Library of Medicine)
• CNS depressants (alcohol, opiates, barbiturates, sedatives, anesthetics)Possible additive or potentiating effect with brimonidine.DailyMed (U.S. National Library of Medicine)

• No adequate data in pregnant women; the US label relies on animal studies only (brinzolamide showed developmental effects at high oral doses in animals); use only if the potential benefit justifies the potential risk to the fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; both substances are excreted in the milk of rats; consider the benefits of breastfeeding and the mother's clinical need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Brinzolamide: Inhibits carbonic anhydrase II in the ciliary processes, reducing aqueous humor secretion (US Simbrinza label).
• Brimonidine tartrate: Alpha-2 agonist that lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.